Categories AlphaGraphs, Earnings, Retail

Earnings: Philip Morris beats Q4 estimates despite 10% top line slip

Philip Morris International (PM) said its revenue for the fourth quarter fell 9.6% to$ 7.5 billion, falling short of the projection of $7.32 billion set by analysts. On an adjusted basis, the maker of Malboro cigarettes earned $1.25 per share, compared to $1.16 per share that the street had expected.

Cigarette and heated tobacco unit shipment volume fell 4.6% in Q4 to 202.4 billion units. Cigarette shipment volumes declined 3.1%, hurt by weakness in East Asia and Europe.

philip morris Q4 2018 earnings infographic

PM shares gained over 4% during pre-market trading. The stock has declined about 24% in the past 52 weeks, hurt by the increased crackdown on tobacco products.

For full year 2019, reported diluted earnings per share is forecast to be at least $5.37, representing a projected increase of at least 5.7%.

CEO André Calantzopoulos said, “We grew our international market share by 0.5 points to reach 28.4%, and maintained a stable share of the cigarette category, highlighting our ability to successfully manage our transition to reduced-risk products.”

Apart from the full year guidance, Philip Morris has announced three targets to be achieved between 2019 and 2021. These include net revenue currency-neutral CAGR of at least 5%, as well as Adjusted EPS currency-neutral CAGR of at least 8%.

The company also aims to achieve heated tobacco unit volume of 90-100 billion units by 2021.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference, and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top